Investment Highlights

• Novel therapeutic products for cancer,  Alzheimer's disease, X-Linked Hypophosphatemic Rickets and osteoporosis

• McGill University owns 2.50%

• World-renowned clinicians, Oncologists, neurologists, and bone biologists
  with proven track records, and solid pre clinical data on a new class of
  cancer drugs